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Individuals with type 2 diabetes mellitus (T2DM) have an increased risk of bone fragility fractures compared to nondiabetic
subjects. This increased fracture risk may occur despite normal or even increased values of bone mineral density (BMD), and
poor bone quality is suggested to contribute to skeletal fragility in this population. These concepts explain why the only
evaluation of BMD could not be considered an adequate tool for evaluating the risk of fracture in the individual T2DM patient.
Unfortunately, nowadays, the bone quality could not be reliably evaluated in the routine clinical practice. On the other hand,
getting further insight on the pathogenesis of T2DM-related bone fragility could consent to ameliorate both the detection of the
patients at risk for fracture and their appropriate treatment. The pathophysiological mechanisms underlying the increased risk
of fragility fractures in a T2DM population are complex. Indeed, in T2DM, bone health is negatively affected by several factors,
such as inflammatory cytokines, muscle-derived hormones, incretins, hydrogen sulfide (H2S) production and cortisol secretion,
peripheral activation, and sensitivity. All these factors may alter bone formation and resorption, collagen formation, and bone
marrow adiposity, ultimately leading to reduced bone strength. Additional factors such as hypoglycemia and the consequent
increased propensity for falls and the direct effects on bone and mineral metabolism of certain antidiabetic medications may
contribute to the increased fracture risk in this population. The purpose of this review is to summarize the literature evidence
that faces the pathophysiological mechanisms underlying bone fragility in T2DM patients.
1. Introduction
Osteoporosis and type 2 diabetes mellitus (T2DM) are chronic
disorders associated with severe morbidity and increased
mortality. Their prevalence, due to the general population
ageing, is rapidly increasing and will early become a global
epidemic imposing an overwhelming burden on health-care
systems [1–7].
Nowadays, skeletal fragility is considered a complication
of T2DM [1]. These patients have an up to 3-fold increased
hip fracture risk [3–5]. Fractures of the wrist and the foot also
seem to be more frequent, while the evidences on vertebral
fractures are more limited [2]. Anyhow, available data sug-
gest a higher risk of vertebral fractures and in particular
morphometric vertebral fractures [6, 7], which has been sug-
gested to be present in a third of T2DM postmenopausal
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women [8]. In T2DM patients, the fracture risk is increased
for any given T-score with respect to the general population,
so that fractures may occur despite a normal or even
increased bone mineral density (BMD) [1, 5, 6], suggesting
that the bone quality alterations rather than the BMD
decrease may be the main factor influencing T2DM-related
bone fragility [9]. Therefore, the assessment of BMD alone
cannot represent a reliable tool to estimate fracture risk [9].
Similarly, fracture risk assessment algorithms, such as the
WHO Fracture Risk Assessment Tool, underestimate frac-
ture risk in these subjects [9–11].
Several pathophysiological mechanisms have been impli-
cated in the deterioration of bone quality in T2DM. From a
clinical point of view, the T2DM duration, the glycemic con-
trol, and the presence of the T2DM-related chronic complica-
tions (i.e., retinopathy, neuropathy, andmacroangiopathy) are
predictors of fragility fractures. Moreover, several T2DM ther-
apies can have a direct negative role on bone metabolism.
Chronic hyperglycemia and advanced glycation end product
(AGE) accumulation, insulin resistance, altered bone marrow
adiposity, inflammatory factors, and adipokines released by
visceral fat and oxidative stress [2, 12] represent the principal
mechanisms of T2DM-induced bone fragility.
Currently, the research in this field is getting rich by new
evidences. Some data suggest that a decrease in hydrogen sul-
fide (H2S), which has a fundamental role for maintaining
bone cell proliferation and differentiation, may be implicated
in the pathogenesis of T2DM-related bone fragility [13].
Finally, starting from the similarities between the cortisol-
related bone loss andT2DM-related bone fragility, the cortisol
secretion, sensitivity, and peripheral activation (the so-called
“cortisol milieu”) have been suggested to play a role in
T2DM-related bone fragility [8, 14, 15].
This review is aimed at exploring the current understand-
ing of the pathophysiological mechanisms underlying
T2DM-related bone fragility.
2. Methodology
According to PRISMA guidelines, PubMed and MEDLINE
were searched from June 1968 to January 2020 for identifying
published articles about bone metabolism and T2DM. In par-
ticular, we considered articles focused on the interactions
between T2DM and bone fragility, such as hyperglycemia,
insulin resistance, AGEs, bone marrow adiposity, inflamma-
tory cytokines, H2S, and cortisol. Studies that analyzed how
T2DM impacts on bone formation and resorption, collagen
formation, skeletal muscle and the incretin system were eval-
uated. Only publications in English were included (Figure 1).
3. Evaluation of Bone Health in T2DM
3.1. Evaluation of Bone Fragility beyond Dual X-Ray
Densitometry (DXA). In T2DM, individual fractures gener-
ally occur at higher BMD levels than in nondiabetic subjects,
with T-score levels being often above the osteoporotic range.
Thus, it has been estimated that in T2DM subjects, an
increase in hip fracture risk, similar than in controls, occurs
at 0.4 and 0.6 SD higher BMD levels in men and women,
respectively [3, 15–17]. On the other hand, the T2DM dura-
tion (i.e., >10 years), insulin treatment, and the presence of
the T2DM-related chronic complications are associated with
fragility fractures regardless of BMD. These evidences justify
the need of a spinal X-ray in patients with T2DM chronic
complications or poorly controlled disease, in addition to
the already fractured ones. Indeed, up to a third of post-
menopausal T2DM women investigated by a lateral spine
radiograph showed asymptomatic morphometric vertebral
fractures [8] that represent a major risk factor for addi-
tional subsequent fractures [18].
Again, considering the inadequate reliability of BMD in a
T2DM population, other imaging techniques have been
investigated in the last years [19]. Different retrospective
and cross-sectional studies have showed that Trabecular
Bone Score (TBS), a textural index based on evaluating pixel
grey-level variations in the lumbar DXA image, providing an
indirect index of bone architecture, is often reduced in
T2DM [19] and that it might predict fracture risk better than
BMD [15, 19–21].
In some cohorts of T2DM patients, the hip structural
analysis (HSA) that represents an additional tool that can
be applied to DXA in order to obtain information on bone
geometry and indirectly assess the bone resistance to axial
compressive forces [22] showed a weaker geometry (e.g., a
narrower neck width) and compromised estimates of skeletal
load response (e.g., a lower buckling ratio) [22]. However, the
additive role of HSA on the prediction of fractures in T2DM
remains to be established.
Although quantitative ultrasound (QUS) devices of the
calcaneus and the phalanxes are widely available and low-
cost techniques, therefore potentially very useful for the
screening of large populations such as the diabetic one, lim-
ited information has been released about their use in
T2DM. Available data showed that QUS parameters may be
useful [23], but data concerning their predictive role in dis-
criminating patients with and without fragility fractures are
conflicting [23, 24]. Moreover, a correlation between reduced
QUS parameters and poor glycemic control or peripheral
nerve dysfunction has been also described [24].
Recently, peripheral quantitative computed tomography
(QCT) and high-resolution peripheral QCT of the distal
radius and tibia have been employed to obtain a 3D assess-
ment of bone size, volumetric BMD, and bone macro- and
microarchitecture (e.g., cortical porosity and trabecular con-
nectivity). Moreover, QCT images can also be employed for
the estimation of the mechanical properties of bone by means
of finite element analysis (FEA) [19]. However, the study
results using these techniques have been quite inconsistent.
Several studies, although not all, suggest that in T2DM
women, the indices of trabecular microarchitecture are pre-
served but cortical porosity is increased and it is specifically
associated with a deficit in biomechanical properties, partic-
ularly in those diabetic females with fragility fractures [25–
28]. Data in T2DM men are even more scarce, but available
ones indicate that the deficits in cortical bone affect both
sexes, at least in older T2DM patients [29].
The use of magnetic resonance imaging to assess trabec-
ular and cortical bone parameters at both peripheral and
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axial skeleton could help in discriminating patients at higher
fracture risk [25]. Remarkably, magnetic resonance spectros-
copy of the vertebral bodies evidenced an altered bone mar-
row fat (BMF) composition (with lower unsaturation of
bone marrow lipids) in T2DM postmenopausal women with
fragility fractures [21]. This approach might represent a
promising tool for fracture risk assessment in the future,
given the negative role of BMF on bone health, as described
later on [18, 25, 26].
Finally, an emerging invasive technique for direct mea-
surement of mechanical characteristics of cortical bone
in vivo is microindentation, which consists of the insertion
of a specific probe into a cortical bone’s surface at the anterior
tibia to induce microscopic fractures. The impact microin-
dentation, from which a ratio called bone material strength
index (BMSi) can be derived as an index of fracture resis-
tance, has been used for the assessment of bone properties
in T2DM. Postmenopausal T2DM women showed signifi-
cantly lower BMSi compared to controls, also after adjust-
ment for BMI and despite similar BMD. Moreover, BMSi
values were found to be negatively correlated with glycemic
control and disease duration [19], thus confirming, using a
direct in vivo measure, compromised bone quality in
T2DM and the potential detrimental effects of prolonged
hyperglycemia on bone.
Currently, the other available techniques beside DXA and
vertebral morphometry, notwithstanding their potential role
for investigating the mechanisms of the T2DM-related bone
fragility, need to be tested in prospective studies and their
scarce availability, high costs, microindentation and also the
invasive nature of the procedure do not consent a routine
use in clinical practice.
In addition to the indications in nondiabetic patients, a
spinal radiograph for evidencing possible asymptomatic ver-
tebral fractures should be performed in T2DM patients with
clinical fragility fracture and/or with T2DM-related chronic
complications, insulin use, and/or long T2DM duration
(i.e., above 10 years).
3.2. Bone Turnover. In T2DM patients, histomorphometric
studies have shown a reduction of the osteoblast number
and of the osteoid amount [30] and a low bone formation
rate [31]. Interestingly, this reduction in bone formation
and mineralized surface has been found in the cancellous,
intracortical, and endocortical surfaces of patients with
T2DM but not of patients with type 1 diabetes [32]. However,
some other data suggested that in addition to the reduction of
the activation frequency of the bone remodeling units, in
some patients, an increase in bone mineralization may be
present. However, in T2DM, the nonenzymatic collagen
crosslinking by pentosidine was found to be increased and
directly associated with glycated hemoglobin (HbA1c) levels
[33]. Overall, these data suggest a low bone turnover state in
T2DM. Interestingly, the pentosidine level has been pro-
posed as a bone fragility marker in T2DM [34, 35].
In keeping with these data, even clinical studies have
shown a reduced bone turnover in T2DM. In particular, both
bone apposition, as mirrored by osteocalcin levels, and bone
resorption, as evaluated by the C-terminal telopeptide of type
I collagen (CTX) levels, were found to be reduced and nega-
tively associated with metabolic control [36–38]. In keeping
with a reduction of bone turnover in T2DM, other markers
of bone apposition and resorption, such as the procollagen
type 1 amino-terminal propeptide and the N-terminal
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Figure 1: PRISMA flow diagram. According to PRISMA guidelines, PubMed and MEDLINE were searched from June 1968 to January 2020
for identifying published articles about bone metabolism and T2DM. In particular, we considered articles focused on the interactions between
T2DM and bone fragility, such as hyperglycemia, insulin resistance, AGEs, bone marrow adiposity, inflammatory cytokines, H2S, and
cortisol. Studies that analyzed how T2DM impacts on bone formation and resorption, collagen formation, skeletal muscle, and the
incretin system were evaluated. Only publications in English were included.
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telopeptide of type I collagen, respectively, were found to be
reduced in patients with T2DM than in nondiabetic controls
[39]. At variance, alkaline phosphatase total activity has
been found to be increased in T2DM patients than in non-
diabetic individuals. Even though both histomorphometrical
and biochemical data point toward a low bone turnover
osteoporosis, some data seem conflicting [37]. It must be
considered, however, that the different studies are frequently
not easily comparable, due to differences in disease dura-
tion, glycometabolic control, presence of chronic complica-
tions, age, ethnicity, and several other differences among
study participants. Importantly, notwithstanding the poten-
tial role of a decrease of bone turnover in reducing the
microcrack repairing in T2DM patients and, thus, in
increasing the fragility fracture risk, we still do not know
whether bone turnover markers can be used to predict frac-
tures in T2DM patients.
Even a role of low levels of parathyroid hormone (PTH)
has been hypothesized in T2DM-related bone fragility [40].
Indeed, some data suggested that a subtle hypoparathyroid-
ism could contribute to low bone turnover in patients with
diabetes mellitus. In keeping with this idea, PTH levels have
been found to be directly associated with CTX, tartrate-
resistant acid phosphatase 5b, and osteocalcin levels [40].
Interestingly, a chronic hypomagnesemia has been hypothe-
sized to impaired PTH secretion in T2DM [41], and a renal
calcium leak induced by glycosuria can determine a negative
calcium balance, which seems to normalize after improving
the glycometabolic control [42].
Summarizing, in the authors’ opinion, the use of bone
turnover markers and/or PTH level determination are not
to be considered mandatory in the vast majority of T2DM
patients. The determination of CTX and PTH levels should
be reserved in doubtful cases (for example, if an additional
secondary cause of osteoporosis is suspected) and on case-
by-case basis.
4. Factors Leading to Bone Fragility in T2DM
4.1. Disease Duration, Insulin Use, Glycometabolic Control,
and Complications. The difficulty in discriminating the inde-
pendent effects of disease duration, metabolic control, and
presence of T2DM complications is due to the existence of
a strong link between these aspects of the T2DM condition.
However, different studies found that a T2DM duration lon-
ger than 10 years significantly increases the fragility fracture
risk, regardless of diabetes control [43–46]. Generally, the
T2DM duration seems to negatively affect bone metabolism,
even though it is important to keep in mind that T2DM may
often remain undiagnosed for many years. Besides T2DM
duration, a poor glycemic control (e.g., HbA1c levels ≥ 7:5
%) has been shown to be associated with increased fracture
risk [47, 48]. A large (i.e., enrolling more than 4 thousand
individuals) long-term prospective (i.e., about 12 years mean
follow-up) study showed that the fracture risk is similar
between nondiabetic subjects and adequately controlled
T2DM patients [49], while the fracture risk was 1.6-fold
increased in subjects with inadequately controlled T2DM.
This relationship between T2DM control and fragility frac-
ture risk was not confirmed in another study, in which, how-
ever, the median levels of HbA1c were only slightly elevated
(~7.5%) [50]. Despite these evidences, it is important to keep
in mind that the predictive value of a single HbA1c value in
the determination of fracture risk is questionable.
Whether T2DM complications could represent indepen-
dent risk factors for bone fragility is still a matter of debate. In
a large case-control study, T2DM itself and all its complica-
tions were significantly associated with an increased overall
risk of fractures [43, 51, 52], without a clear evidence of the
independent contribution of each single factor. Interestingly,
both neuropathy and insulin use may influence the risk of
falls [53–55], which are of crucial importance in these
patients, being associated with an increased risk of fracture,
hospitalization, and death [56]. Indeed, as compared to non-
diabetic subjects, the risk of falling more than once a year is
known to be increased in older women with T2DM without
insulin use and even higher in insulin users [54]. Sarcopenia,
the age-related decline in skeletal muscle mass, quality, and
function, may represent an additional contributing factor to
the increased fall and fracture [57], and it is known to be
associated with T2DM. Indeed, in T2DM patients, both mus-
cle strength and function are decreased as compared to non-
diabetic subjects [58, 59]. In addition, T2DM patients can
present neuromuscular dysfunction, which may favor falls
irrespective of sarcopenia [60]. However, the evidences of
association between sarcopenia, fall risk, and bone fragility
in T2DM cohorts are still limited.
Finally, some studies found an association between micro-
vascular disease and bone microstructure as well as with frac-
ture risk. This association might be explained by an altered
vascular supply to the skeleton, in particular cortical bone, that
may contribute in compromising bone formation [2].
Overall, in our opinion, great attention should be
reserved to T2DM patients, who have a long-standing disease
and/or chronic complications and/or are insulin treated.
4.2. Oral Antidiabetic Agents. The effect of oral antidiabetic
agents on bone is summarized in Table 1. Among the possi-
ble mechanisms contributing to the increased risk of fracture
in T2DM, the use of antidiabetic drugs with direct effects on
bone cells or an indirect effect on bone metabolism has to be
taken into consideration.
Metformin, the worldwide accepted first-line drug in the
treatment of T2DM [61], exerts its effect decreasing liver glu-
cose production, enhancing insulin sensitivity, and inhibiting
fatty acid synthesis and promoting their oxidation [62]. In
most animal studies, metformin seems to improve bone mass
and strength [2, 63], by preventing the advanced glycation
end product (AGE) accumulation, known to induce alter-
ations in the osteoblastic cells. Moreover, metformin has
been suggested to inhibit the formation of reactive oxygen
species (ROS) and apoptosis in osteoblastic cultures exposed
to high glucose concentrations [63]. Unfortunately, the evi-
dence of a positive effect on bone of metformin administra-
tion in T2DM patients is less impressive and somewhat
conflicting. However, overall metformin is reported having
positive or neutral effects on fracture risk in T2DM patients
[46, 64–66].
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Table 1
Metformin
Preclinical Ref. Effect
[2, 63]
↑ Bone mass and bone strength
↓ AGE accumulation
↓ ROS formation
↓ Osteoblast apoptosis
Clinical Ref. Characteristics Fracture risk
[46]
Prospective cohort study among 1964 Rochester residents
who first met glycemic criteria for diabetes in 1970-1994
(mean age, 61:7 ± 14:0 yr; 51% men)
The risk was decreased among users of biguanides (HR,
0.7; 95% CI, 0.6-0.96)
[64]
Prospective cohort study, based on data from the
Osteoporotic Fractures in Men (MrOS) study that
enrolled 5,994 men (aged ≥65 years)
Metformin did not increase the risk of nonvertebral
fracture
[65] Case-control study based on 498,617 subjects in Denmark Decreased risk of fractures
[66] Population based study among 206,672 individuals
There was no association of hip fracture with cumulative
exposure to metformin
Overall: ↓ = fracture risk
Sulfonylureas
Preclinical Ref. Effect
[2, 61,
63]
↑ Osteoblast proliferation and differentiation
Clinical Ref. Characteristics Fracture risk
[46]
Prospective cohort study among 1964 Rochester residents
who first met glycemic criteria for diabetes in 1970-1994
(mean age, 61:7 ± 14:0 yr; 51% men)
No significant influence on fracture risk was seen with
sulfonylurea
[65] Case-control study based on 498,617 subjects in Denmark
Use of sulfonylureas was associated with a decreased risk
of any fracture
[66] Population-based study among 206,672 individuals
There was no association of hip fracture with cumulative
exposure to sulfonylureas
[67]
Retrospective observational study on 361,210 patients
with type 2 diabetes
ICD-9-CM-coded outpatient hypoglycemic events were
independently associated with an increased risk of fall-
related fractures
[69]
Cross-sectional study on 838 Japanese patients with
T2DM
Decreased risk of vertebral fractures in postmenopausal
women (OR = 0:48, P = 0:018)
Overall: ↓ = fracture risk, ↑ fall risk due to hypoglycemia
Thiazolidinediones
Preclinical Ref. Effect
[2, 63]
↑ Osteoclastogenesis
↑ Osteocytes apoptosis
[70–72]
↑ Bone marrow adipogenesis
↓ Osteoblastogenesis
Clinical Ref. Design Fracture risk
[73]
Longitudinal study on ADOPT data from 1,840 women
and 2,511 men with T2DM
The increase in fractures with rosiglitazone representing
hazard ratios (95% CI) of 1.81 (1.17-2.80) and 2.13 (1.30-
3.51) for rosiglitazone compared with metformin and
glyburide occurred in pre- and postmenopausal women,
and fractures were seen predominantly in the lower and
upper limbs
[76]
Nested case-control study based on data of 32,466 T2DM
from the Longitudinal Health Insurance Database 2000
(LHID2000) and the catastrophic illness patient registry
(CIPR) in Taiwan
Increased risks for fracture in patients who used TDZs,
especially in female patients younger than 64 years old, for
whom the risk was elevated from a 1.74- to a 2.58-fold
odds ratio
Overall: ↑ fracture risk (peripheral fractures)
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Table 1: Continued.
Incretins
Preclinical Ref. Effect
[2, 63]
DPP-4 inhibitors
↓ Bone resorption; ↑ trabecular and cortical bone volume
[82, 83]
GLP1-RA
↑ Proliferation of bone marrow mesenchymal stem cells; ↓ differentiation adipocytes; ↓ sclerostin expression
Clinical Ref. Design Fracture risk
[85]
Meta-analysis including 16 RCTs and a total of 11,206
patients to study the risk of bone fractures associated with
liraglutide or exenatide, compared to placebo or other
active drugs
Liraglutide treatment was associated with a significant
reduced risk of incident bone fractures (MH −OR = 0:38,
95% CI 0.17-0.87); however, exenatide treatment was
associated with an elevated risk of incident bone fractures
(MH −OR = 2:09, 95% CI 1.03-4.21)
[86]
Meta-analysis including 7 RCTs to assess GLP-1Ra-
related fracture risk compared with other antidiabetic
drugs
Use of GLP-1Ra does not modify the risk of bone fracture
in T2DM compared with the use of other antidiabetic
medications
[88]
A case-control study nested within a cohort of 1,945
diabetic outpatients with a follow-up of 4:1 ± 2:3 yr
No significant association was observed between bone
fractures and medications
[89]
A retrospective analysis of real-world data that matched
4160 DPP4i ever users to never users in metformin-
treated T2DM patients (mean age 61 ± 11 yr), in Germany
The use of DPP-4 inhibitors was associated with a
significant decrease in the risk of developing bone
fractures (all patients HR = 0:67, 95% CI 0.54-0.84;
women HR = 0:72, 95% CI 0.54-0.97; men HR = 0:62,
95% CI 0.44-0.88)
[90]
Meta-analysis based on 51 RCTs (N = 36,402; mean age
57 ± 5 yr), to assess fractures in T2DM, comparing DPP-4
inhibitors with either an active agent or a placebo
No association of fracture events with the use of DPP-4
inhibitor when compared with placebo (OR; 0.82, 95% CI
0.57-1.16; P = 0:9) or when DPP-4 inhibitor was
compared against an active comparator (OR; 1.59, 95% CI
0.91-2.80, P = 0:9)
Overall: ↓ fracture risk with liraglutide; =↓ fracture risk
with DPP-4 inhibitors
SGLT-2 inhibitors
Preclinical Ref. Effect
[94]
↑ Urinary calcium
↓ Serum PTH levels
Clinical Ref. Design Fracture risk
[92]
Meta-analysis on 20 studies including 8,286 patients
treated with SGLT-2 compared with placebo
Not increased fracture risk; pooled risk ratio of bone
fracture in patients receiving SGLT2 inhibitors versus
placebo was 0.67 (95% confidence interval, 0.42-1.07)
[93]
Cumulative meta-analysis of 38 RCTs (10 canagliflozin,
15 dapagliflozin, and 13 empagliflozin) involving 30,384
patients
Compared with placebo, canagliflozin (OR 1.15; 95% CI
0.71-1.88), dapagliflozin (OR 0.68; 95% CI 0.37-1.25), and
empagliflozin (OR 0.93; 95% CI 0.74-1.18) were not
significantly associated with an increased risk of fracture
[96]
Randomized phase 3 study on 10,194 T2DM patients to
describe the effects of canagliflozin on bone fracture risk
Fracture risk was increased with canagliflozin treatment
and may be mediated by falls
Overall: = fracture rate or ↑ by canagliflozin
Insulin
Preclinical Ref. Effect
[97–99]
↑ Bone anabolism; ↓ bone resorption
↑ BMD
Clinical Ref. Design Fracture risk
[46]
Prospective cohort study among 1964 Rochester residents
who first met glycemic criteria for diabetes in 1970-1994
(mean age, 61:7 ± 14:0 yr; 51% men)
Increased fracture risk in patients on insulin (HR, 1.3; 95%
CI, 1.1–1.5)
[64]
Prospective cohort study, based on data from the
Osteoporotic Fractures in Men (MrOS) study that
enrolled 5,994 men (aged ≥65 years)
The risk of nonvertebral fracture increased only among
men with T2DMwho were using insulin (HR 1.74, 95% CI
1.13, 2.69)
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The role of sulfonylureas (insulin secretagogues, blocking
ATP-regulated K+ channels, that enhance insulin release
from pancreatic β-cells) on bone metabolism has been inves-
tigated only in few studies [61]. Available data evidence a
potential stimulatory effect on osteoblast proliferation and
differentiation and a protective role on osteoblasts against
hyperglycemia [2, 63]. However, some studies reported an
increased risk of falls and fractures that might be due to the
increased risk of hypoglycemia associated with the use of
these drugs [64, 67], while other studies reported a neutral
or even positive effect on fracture risk [46, 65–69].
Pioglitazone and rosiglitazone, known as thiazolidine-
diones (TZDs), activating peroxisome proliferator-activated
receptor gamma (PPARγ), reduce the extent of insulin resis-
tance and improve β-cell response towards altered glucose
levels. Despite the beneficial effect of TZDs on glycemic con-
trol, their prolonged use has been associated with negative
effects on bone metabolism. Interestingly, in bone marrow
stromal stem cells (BMSC), PPARγ activation increases adi-
pogenesis and decreases osteoblastogenesis [70–72]. In keep-
ing, TZDs have been shown to decrease bone formation,
increase osteoclastogenesis, and promote osteocyte apopto-
sis [2, 63]. Several clinical studies have shown that in
patients using TZDs, the bone formation markers decrease,
while the bone resorption markers increase and BMD
declines [2, 63]. Moreover, randomized controlled trials
and prospective studies revealed an increased peripheral
fracture risk in TZD-treated patients, especially in postmen-
opausal T2DM women [72–76]. Furthermore, BMD loss
observed in TZD users seems to be not reversible after treat-
ment discontinuation [77].
Gastric inhibitory polypeptide (GIP) and glucagon-like
peptide 1 (GLP-1) are gut-derived hormones that stimulate
insulin, suppress glucagon secretion, inhibit gastric empty-
ing, and reduce appetite and food intake (so-called “incretin
effect”). Patients with T2DM have a reduced incretin effect
[78]. The therapeutic approaches for restoring the incretin
action include degradation-resistant GLP-1 receptor agonists
(GLP-1 mimetics) and inhibitors of dipeptidyl peptidase-4
(DPP-4) activity [79]. The presence of GLP-1 and GIP recep-
tors in human osteoblastic cells at different stages of differen-
tiation induced many authors to investigate the effect of these
gut-derived hormones on bone metabolism [80]. Moreover,
GLP-1 receptors are expressed even in BMSC and immature
osteoblasts [81]. Several evidences suggest that GLP-1 stimu-
lates proliferation of mesenchymal stem cells and inhibit
their differentiation into adipocytes [82]. In vivo studies
showed an osteogenic effect of GLP-1 that seems to be medi-
ated through the inhibition of the expression of the sclerostin
gene [83] and of the WNT pathway [81]. A study in rodents
showed that the higher the doses of exendin-4 (a GLP-1
mimetic), the higher the increase in bone strength and bone
formation [84].
From a clinical point of view, few meta-analyses or post
hoc analyses of population-based studies have been per-
formed on the relation between the incretin use and bone fra-
gility in T2DM and showed conflicting results. A recent
meta-analysis of 16 RCTs on the effect on fracture risk of
the GLP-1 receptor agonists showed that, among the GLP-1
mimetics, while the exenatide use was associated with an
increased fracture risk with respect to other antidiabetic
agents, the liraglutide use was associated with a significantly
reduced risk of fractures [85]. However, other studies did
not report significant effects of GLP-1 receptor agonist frac-
ture risk and BMD [86, 87]. Also, for DPP-4 inhibitors, avail-
able data are conflicting. In vitro studies show a neutral effect
on osteoblast differentiation. However, in animal models,
these agents have been found to increase trabecular and cor-
tical bone volume, due to a suppression of bone resorption [2,
63]. As far as study in humans is concerned, although two
clinical studies showed a positive effects on fracture preven-
tion in patients treated with the DPP-4 inhibitors [88, 89],
a recent meta-analysis reported a neutral role of these agents
[90]. Overall, it should be underlined that none of these stud-
ies were specifically designed to assess the effect of DPP-4
inhibitors or of incretins on fracture prevention, and the
information regarding fractures has been obtained only by
analyzing the safety profile. This explains the small fracture
number emerged from these studies.
A new class of blood glucose-lowering drug for T2DM is
represented by the sodium-glucose cotransporter-2 (SGLT-
2) inhibitors. These drugs inhibit SGLT2 in the proximal
convoluted tubule preventing the reabsorption of glucose
and inducing its excretion in urine. Importantly, even the
tubular phosphate reabsorption is increased by using these
agents. Available preclinical and clinical data suggest that
the SGLT2 inhibitors might negatively affect bone health,
but data on fracture risk are controversial [2]. Indeed, two
pooled analyses of RCTs reported neutral effects of SGLT-2
inhibitors on fracture [91–93], while other studies found
an increased fracture incidence, more evident with the use
of canagliflozin, with fractures occurring already after 12
weeks of drug initiation and increasing over time [94–96].
At present, it is not clear whether the bone negative effects
of SGLT-2 inhibitors are mechanism-based or compound-
specific.
Even though no specific study regarding oral antidiabetic
agents and fracture risk is available, in our opinion, a
Table 1: Continued.
[43] Prospective study on 3,654 older Australians
Insulin treatment was associated with increased fracture
risk (adjusted RR 5.9, 95% CI 2.6-13.5)
[101]
Prospective cohort study based on data from 9654 women,
aged >65 yr in the Study of Osteoporotic Fractures
Insulin-treated diabetics had more than double the risk of
foot (multivariate adjusted RR, 2.66; 95% CI, 1.18-6.02)
fractures compared with nondiabetics
Overall: ↑ fracture risk (especially nonvertebral fracture)
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particular attention at bone health should be paid in patients
treated with TZDs and/or canagliflozin.
4.3. Insulin. The available data on the effect of insulin on
bone are summarized in Table 1. In the presence of a treat-
ment failure with the oral antidiabetic medications, insulin
therapy represents the elective therapy for T2DM patients.
In preclinical studies, insulin seems to play an important role
in bone metabolism, in keeping with the presence of insulin
growth factor receptors (IGFRs) on the surface of both oste-
oclasts and osteoblasts. In vivo and in vitro studies estab-
lished that insulin exerts an anabolic effect on bone [97].
Mice with altered insulin signaling, due to the lack of IGFRs,
have low bone turnover and reduced BMD [98]. On the other
hand, insulin injection is able to induce bone formation,
inhibit bone resorption, and lead to BMD improvement in
adult mice [99].
At variance, in most clinical studies, the positive effect of
the insulin treatment on both bone turnover markers and
BMD [100] is not evident. Rather, its use has been associated
with a higher risk of fractures (in particular, nonvertebral
ones) [43, 46, 64, 101]. In a recent study on a large cohort
of T2DM patients, insulin monotherapy was clearly associ-
ated with a 1.6-fold increased fracture risk in respect with
metformin monotherapy [102]. However, recent data show
that the use of long-acting insulins, less apt to induce hypo-
glycemia, was associated with a lower fracture risk as com-
pared to other insulins [103], suggesting that, at least in
part, the higher fracture risk associated with the insulin use
might depend on a higher risk of hypoglycemia-related fall.
Overall, it should be considered that insulin-treated T2DM
patients have generally a longer disease duration and a higher
number of comorbidities that could per se influence the frac-
ture risk, regardless of the insulin use.
Eventually, is important to note that, although a relative
insulin deficiency occurs in the later stages of T2DM, the pre-
dominant defect in this condition is the insulin resistance.
We still do not know how insulin resistance affects bone
and whether or not the skeletal loading might be compro-
mised due to decreased muscle strength secondary to
decreased glucose uptake by muscles.
As already mentioned, in the authors’ opinion, insulin
treatment has to be considered a risk factor for fragility frac-
ture in T2DM patients.
4.4. Glucose Toxicity. As evidenced above, many evidences
point toward a reduced bone turnover in T2DM, with a neg-
ative correlation between glycometabolic control and bone
apposition and resorption markers. Hyperglycemia exerts
troublesome effects on osteoblastogenesis since the early
steps of differentiation, ultimately leading to low bone turn-
over. High blood glucose levels may reduce MSC viability
and clonogenicity [104]. Several in vitro studies showed, in
the presence of hyperglycemia, a downregulation of the
BMSC proliferation, osteoblast gene expression, alkaline
phosphatase (ALP) activity [105], and bone mineralization
rate in BMSC isolated from streptozotocin- (STZ-) induced
diabetic rats [105]. In addition, BMSC exposed to chronic
high glucose exhibit enhanced adipogenic rather than osteo-
genic pathway, due to the PPARγ activation, and an
enhanced expression of cyclin D3 [106] and decreased
Runt-related transcription factor 2 (RUNX2) [107], ALP
[108], and osteocalcin expression in osteoblasts. In keeping,
studies in animal models confirmed a reduced mineralization
and decreased trabecular bone volume in T2DM, probably
due to the decreased RUNX2 gene expression and to reduc-
tion of osteocalcin, osteoprotegerin, bone morphogenetic
protein-2 expression, and ALP [109–113] (Figure 2).
Recently, some evidences suggest that even the osteo-
cytes, the most abundant bone cell type orchestrating bone
remodeling, are affected by hyperglycemia. Indeed, in
T2DM, sclerostin and Dickkopf-related protein 1 (Dkk1),
two major contributors of bone formation via Wnt signaling
inhibition, are increased and β-catenin is reduced [109].
Increased serum levels of sclerostin have been observed in
T2DM patients [114] and have been shown to be associated
with vertebral fractures [115]. In addition, in T2DM patients,
the usual PTH-induced transcriptional suppression of scler-
ostin production is lost. In keeping, the treatment with scler-
ostin antibodies improves bone mass and strength in T2DM
animal models.
Overall, these cellular and animal models indicate that in
T2DM, a preferential differentiation of the BMSC toward
adipocytes rather than osteoblast lineage is present. Interest-
ingly, even clinical data are in line with this theory. Indeed,
recent studies show that in T2DM, an inverse association
exists between marrow adipose tissue (MAT) and glycemic
control and T2DM women with poor glycemic control have
significantly higher MAT levels than those with adequate gly-
cemic control [116, 117]. The functional significance of MAT
and its implications for bone quality remain to be clarified, as
well as the relationship between MAT and other fat depots
(i.e., visceral and subcutaneous fat stores) and possible hor-
monal determinants. Interestingly, another possible mecha-
nism that may elucidate the prevalence of adipogenesis on
osteoblastogenesis is the PI3K/Akt pathway, which is acti-
vated by the reactive oxygen species (ROS) production,
which, in turn, is associated with hyperglycemia (Figure 2).
We know that AGE levels are increased in T2DM as a
result of prolonged hyperglycemia and oxidative stress. The
activation of AGE receptor, expressed in human-derived
bone cells, enhances inflammatory cytokine production and
ROS production, triggering a vicious cycle of inflammation
and bone resorption [118]. Moreover, AGEs may reduce
the expression of RUNX2, osteocalcin, and osterix [119],
which are well-known important factors in osteoblast differ-
entiation. Furthermore, on the one hand, AGEs suppress
endoplasmic reticulum function, essential to osteoblast dif-
ferentiation and activity [120] and, on the other hand, they
increase osteoblast apoptotic death [119]. All these mecha-
nisms induce a reduction of mineralization [31, 121] and a
bone quality impairment. Finally, hyperglycemia may play
a negative role also in osteoclastogenesis, inducing an
impaired bone resorption. Hyperglycemia could especially
impair embryonic stem cell differentiation in osteoclast, usu-
ally promoted by physiological glucose levels. In keeping with
this, STZ-induced diabetic mice present impaired bone
resorption due to reduced levels of dendritic cell-specific
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transmembrane proteins involved in osteoclast differentia-
tion [122, 123]. However, other evidences show elevated
bone resorption and osteoclast activity [111, 113] that may
compromise the mineralization [124] (Figure 2).
Hyperglycemia exerts its negative effect on bone health
also acting on extracellular matrix. It is well known that bone
elasticity, toughness, and strength are dependent on the type
of cross-links between the adjacent collagen molecules, while
the mineral component of the bone matrix provides stiffness.
Indeed, while enzymatic cross-links are essential to maintain
bone strength, the formation of nonenzymatic AGE cross-
links within collagen fibers negatively affects bone strength
[125]. The low turnover of collagen leads to the accumulation
of a huge quantity of altered type 1 collagen, which may
induce, at both trabecular and cortical levels, biomechanical
changes [126]. In addition, both in vitro and in vivo animal
and human studies demonstrated that trabecular bone is sus-
ceptible to the accumulation of nonenzymatic glycation,
which increases its propensity to fracture and decreased flex-
ion strain and energy (Figure 2).
In an animal model, pentosidine levels and the pentosidi-
ne/total enzymatic cross-link ratio were negatively associated
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Figure 2: Mechanisms underlying bone fragility in type 2 diabetes mellitus (T2DM). In T2DM, the muscle tissue reduction, due to several
factors including hyperglycemia per se, but probably also hydrogen sulfide (H2S) decrease, is thought to have a negative role on osteoblast
lineage, via its crosstalk with the brown adipose tissue. Indeed, the muscle tissue is known to influence the brown adipose tissue,
physiologically stimulating the secretion of factors (such as IGFBP2 and Wnt10b) thought to be important for osteoblast proliferation and
activity. Osteoblast differentiation and activity, in T2DM, may be also impaired directly by the reduction of H2S levels that physiologically
are thought to stimulate the osteoblast lineage. Hyperglycemia may directly reduce bone mesenchymal stem cell (MSC) viability and
clonogenicity and also have an indirect negative effect on osteoblasts via the accumulation of advanced glycation end products (AGEs),
which negatively affects osteoblasts through a reduction of the insulin-like growth factor-1 (IGF1) levels. The AGE accumulation impairs
the normal collagen formation and leads to reactive oxygen species (ROS) increase that may augment marrow adiposity via the
phosphoinositide-3-kinase–protein kinase B/Akt (PI3K/Akt) pathway. The inflammatory cytokine increase, directly and/or indirectly (due
to the H2S reduction), may also impair osteoblastogenesis and increase osteoclast activity and ROS, ultimately leading to bone adiposity.
Finally, in T2DM, osteoblasts may be also damaged by the low adiponectin levels due to the increase of white adipose tissue, which is a
characteristic of T2DM itself but also a consequence of low H2S levels. Finally, even an altered cortisol secretion, peripheral activation,
and sensitivity (i.e., “cortisol milieu”) have been suggested to potentially impair osteoblast activity.
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with some mechanical bone properties such as energy
absorption, stiffness, maximum load, and elastic modules
[127]. Plasma and/or urinary pentosidine has been investi-
gated as a potential clinical marker of bone damage in
T2DM. In a T2DM Japanese cohort, pentosidine levels have
been found significantly higher in postmenopausal women
with vertebral fractures [34] than in nonfractured ones,
regardless of the glycemic control, BMD, other osteoporosis
risk factors, and renal function, all factors known to affect
pentosidine levels.
Although these observations suggest that the impairment
in collagen cross-links and AGE formation might explain the
reduced bone quality in T2DM, larger and more robust stud-
ies are needed to confirm this hypothesis and to allow pento-
sidine being used as a marker for fracture prediction in
T2DM patients.
4.5. Insulin Growth Factor 1 (IGF1), Inflammatory Cytokines,
Brown/Beige Fat, and Adipokines. In T2DM, bone fragility is
conceivably linked to an altered regulation of insulin growth
factors (IGFs). Several in vivo studies have shown that high
concentration of AGEs blunt the stimulatory IGF1 action
on osteoblasts, probably through an osteoblast resistance to
the IGF1 action [128, 129]. In postmenopausal women
affected with T2DM, IGF1 were found to be inversely associ-
ated with the presence and the number of vertebral fractures,
regardless of T2DM control, age, spinal BMD, renal function,
and insulin secretion [130] (Figure 2).
Overall, T2DM is often described as a state of accelerated
ageing. Inflammatory cytokines have been embroiled in the
T2DM development as well as in its micro- and macrovascu-
lar complications. Inflammatory cytokines seem to have a
role also in T2DM-related bone disease. Indeed, osteoclasto-
genesis can be activated by elevated cytokine levels, while
osteoblast differentiation can be suppressed [131, 132].
Importantly, obese T2DM subjects show significantly higher
levels of interleukin-6 and tumor necrosis factor-alfa that, at
tissue level, may induce the ROS production, therefore affect-
ing differentiation and survival of osteoblasts, osteoclasts,
and osteocytes [133] (Figure 2).
Brown adipose tissue, which is typically thermogenically
active, has been found to be reduced in T2DM and obesity
[134]. Insulin-like growth factor-binding protein-2 and
Wnt10b, factors secreted by brown adipose tissue, have an
anabolic effect on bone metabolism and increase osteoblast
activity [135]. In addition, the inactivation of TGFβ–
SMAD3–myostatin signaling [136] promotes the browning
of adipocytes. These recent data encourage the development
of a novel class of TGFβ–myostatin antagonists that could
be potentially used to treat both obesity and the T2DM-
related bone disease (Figure 2).
Dysregulation of serum adipokine levels is also possibly
linked to the T2DM-related low bone turnover. Indeed,
T2DM patients present low adiponectin levels, an adipokine
exclusively produced by the adipose tissue [137]. In vitro,
adiponectin seems to have an inhibitory effect on osteoclasts
and an anabolic effect on osteoblasts [138]. However, the
studies aimed at investigating the link between adiponectin
and BMD gave conflicting results, some data showing an
inverse relationship [139, 140], while others showing a posi-
tive relationship between adiponectin and BMD at distal
radius [141]. Furthermore, T2DM patients present low levels
of leptin, another adipokine produced by white adipose tissue
as well as by osteoblasts and bone marrow adipocytes. A
Japanese study showed a significant negative correlation
between leptin and bone resorption in T2DM subjects. More-
over, these authors showed that distal radius BMD was asso-
ciated with leptin levels, but this association was not present
for spine and hip BMD [141]. These results suggest that adi-
pokines may exert a differential effect on cortical versus tra-
becular bone [142].
Further research is needed to confirm if the adipokine
levels may be associated with bone disease in T2DM and if
their determination may be useful in the clinical practice
(Figure 2).
4.6. Obesity, T2DM, and Bone Fragility: A Concept of
“Circular Health” in Body Energy Control. Human health
can be regarded as a system of communicating vessels, partic-
ularly true when abnormalities in the management of the
energy balance exist. The concept of “circular health” would
suggest an interdisciplinary approach to identify and treat
the multifactorial determinants of chronic diseases. The abil-
ity to adapt and adjust to different environmental conditions
has been enabling the humans in survival. In a period of fam-
ine or hunger, the following conditions occur: (a) decrease in
basal metabolic rate, leptin production, muscle mass, and
lipolysis and (b) increase in cortisol secretion and lipogenesis.
The opposite occurs when abundant food is available. Cur-
rently, in industrialized countries, rarely radical fluctuations
in diet and metabolism occur, and, consequently, unfavor-
able health conditions such as obesity and diabetes mellitus
develop. Over the past 20 years, it has been suggested that
human skeleton may exert an important role also in energy
metabolism through “local” hormonal connection, such as
adipokines, mainly released by adipose tissue, but not exclu-
sively, insulin/insulin-like growth factor 1 (IGF1), and osteo-
calcin/undercarboxylated osteocalcin pathways [143, 144],
together with organs known to be involved in metabolic con-
trol. Such molecular pathways may be fundamental in main-
taining energy homeostasis by controlling and coordinating
both “fuel” uptake and energy expenditure in the human
body, probably within a more complex network in which also
central nervous system neurons and peripheral energy cen-
ters, sensing and regulating the energy needs, cooperate.
The common cellular origin of osteoblasts, myocytes, and
adipocytes makes not surprising the hypothesis that the skel-
eton either has a role in energy metabolism or may suffer in
both skeletal muscle and adipose cell diseases, even if the
underlying molecular mechanisms involved are still to be
understood. Diabetic animal models and in vivo human
studies suggested a strict interaction between whole body
metabolism and skeletal health. It is well known that obesity
and T2DM have a negative impact on fracture risk, but the
knowledge on possible interactions of obesity, T2DM, and
fracture still needs to be elucidated. Several studies suggested
that alterations of adipose tissue-released hormones, such as
adipokines, may exert harmful effects on bone cells. In
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particular, an in vitro study revealed that adiponectin, pro-
duced by adipose tissue, may exert either an anabolic effect
on osteoblasts or an inhibitory effect on osteoclasts [138],
and low levels of adiponectin are found in patients with
T2DM [137]. However, conflicting results concerning a clin-
ical evidence on the link between adiponectin and BMD exist
[139–141]. Impaired leptin production, produced by white
adipose tissue, bone marrow adipocytes, and osteoblasts,
has been observed in diabetic patients, and a significant
negative correlation between its serum levels and the bone
resorption marker urinary NTX has been reported in
T2DM Japanese subjects, who showed a significant positive
correlation between serum levels of leptin and Z-scores at
the distal radius but neither at the lumbar spine nor at femo-
ral neck levels, as if a differential effect on cancellous versus
cortical bone existed [141, 142]. A fracture-related morbidity
seems to be a higher in obese than in nonobese women [145].
Higher fat depots negatively act on bone, and the cytokines
produced by visceral fat exhibit a proresorptive effect while
an increased intramuscular fat accumulation associates with
a reduced and less effective skeletal muscle function, power-
ing both the attenuation of loading effects and the increase
of risk for falls typically observed also in T2DM [146]. Meta-
bolic syndrome, a cluster of cooccurring conditions highly
increasing the risk for cardiovascular heart diseases, T2DM,
excess body fat around the waist, and abnormal cholesterol
or triglyceride levels, and dysmobility syndrome, a cluster
of coexisting conditions such as osteoporosis, sarcopenia,
obesity, ultimately increasing the risk for falls and fractures
in affected subjects [147], may coexist in obese-T2DM
patients. However, a common denominator in both syn-
dromes, represented by higher individual fragility and
impairment of the energy balance of the body, either as its
generation or its dissipation/transformation, can be hypoth-
esized. The importance of these metabolic pathways is under-
lined by common metabolic diseases, such as osteoporosis,
diabetes, and obesity, caused by genetic or environmental
disturbances in endocrine control mechanisms. The impact
of coexisting obesity and diabetes determines rising health
costs and disability, other than a poor health status.
In a circular health model, a common multitasking
diagnostic-clinical-therapeutic management of these patients
is to be recommended [148, 149].
4.7. Cortisol Secretion, Peripheral Activation, and Sensitivity.
The low bone turnover with a decreased osteoblastic function
typical of the T2DM-related bone damage is also a feature of
the glucocorticoid-induced osteoporosis. Interestingly, in
T2DM patients, the cortisol secretion and/or sensitivity have
been suggested to influence the diabetic disease. Indeed, in
T2DM patients, an increased (even though still within the
normal range) cortisol secretion is present, particularly in
those affected with the diabetic complications [13] and the
different glucocorticoid receptor (GR) gene polymorphisms
have been found to potentially influence the disease control
[150]. Interestingly, the cortisol secretion and sensitivity (as
represented by the N3S3S sensitizing variant of GR gene)
have been suggested to be associated with the presence of
asymptomatic vertebral fractures in postmenopausal T2DM
patients [8, 14]. These clinical data, suggesting a potential
role of the degree of cortisol secretion and sensitivity in the
T2DM-related bone osteoporosis, are in line with recent
in vitro data showing that the shift in the balance between
osteoblastogenesis and adipogenesis of MSC may be medi-
ated by the GR genetic variants [151]. In addition, even the
degree of the interconversion of cortisone in cortisol at the
peripheral tissue levels (including bone), due to the activity
of the 11βhydroxysteroidodehydrogenase type 1 (11HSD1),
may influence bone in T2DM. Indeed, the selective inhibition
of 11HSD1, which has been suggested as potential treatment
for T2DM in humans [152], has been also demonstrated to
improve diabesity and osteoblast differentiation in a mouse
model [153]. Finally, in T2DM, a vicious circle could be
hypothesized between cortisol “milieu,” bone, and glycome-
tabolic control. Indeed, the low bone turnover induced by
the increased cortisol secretion, peripheral activation, and
sensitivity could contribute in reducing the undercarboxy-
lated osteocalcin levels [154], which, in turn, could worsen
the glycometabolic control, eventually leading to a perpetua-
tion of low bone turnover (Figure 3).
These data may have an important clinical application.
Indeed, if bone damage in T2D were related, at least partially,
to the degree cortisol secretion and/or sensitivity, the treat-
ment with an 11HSD1 inhibitor could improve glycometa-
bolic control and reduce the fracture risk at the same time.
At present, however, the clinical usefulness of the cortisol
“milieu” assessment for individuating T2DM patients at risk
of fracture is still to be determined.
4.8. Hydrogen Sulfide. Hydrogen sulfide (H2S) is a new gas-
eous signaling molecule which acts as a key messenger in
many physiological and pathological conditions. Endoge-
nously, H2S is produced within cells by the catabolic pathway
of sulfurated amino acids, also known as the transsulfuration
pathway, by means of the two enzymes cystathionine beta-
synthase (CBS) and cystathionine gamma-lyase (CSE)
[155]. Physiologically, H2S freely diffuses through cell mem-
branes and is released in the circulation, where it can be
present in the form of free H2S or bound sulfane sulfur.
Decreased nitric oxide (NO) bioavailability and deficiency
of H2S are considered to be involved in the pathophysiology
of both T2DM [155] and osteoporosis [156]. Cystathionine
beta-synthase is abundantly expressed in several tissues and
in particular in BMSC, in insulin-secreting pancreatic β-cells,
and several studies showed a role of H2S in both inhibition of
insulin secretion mediated by ATP-sensitive K+ channels
and a pro- or antiapoptotic effects on β-cells [157] and in
skeletal muscles. Most studies indicate that in both animal
models of diabetes and T2DM patients, H2S blood levels
are decreased.
In BMSC, H2S has a fundamental role for maintaining
cell proliferation and differentiation [158]. Indeed, H2S
deficiency in BMSC attenuates both osteogenesis and prolif-
eration. In keeping with this, CBS-deficient mice have
decreased serum and intracellular levels of H2S and a severe
osteoporotic phenotype [158, 159]. The H2S administration
to CBS deficient mice of can restore normal bone homeosta-
sis [158]. One of the supposed mechanisms is the increase of
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Hcy that leads to and oxidative damage and dysfunction of
the BMMSCs. Moreover, several studies showed that osteo-
porosis derived from estrogen deficiency is associated to a
defective H2S biosynthesis [160] and the treatment with an
H2S donor prevents the bone loss induced by stimulating
bone formation through the activation of the Wnt signaling
cascade by increased production of the Wnt ligands.
H2S regulated insulin sensitivity, gluconeogenesis, and
glycogenolysis and inhibits glucose utilization and glyco-
gen storage. It seems also to regulate adipose tissue lipoly-
sis, adipokine production, and inflammation, processes
important for local and systemic insulin sensitivity [161]
(Figure 2).
Recently, a study showed, in a rat model of diabetes, a
reduced expression of CBS and other enzymes involved in
H2S production in skeletal muscles and suggested a possible
relationship between sarcopenia and H2S deficiency. Indeed,
in this animal model, the treatment with H2S donor showed
to lead to an improvement in muscle mass and functionality
(Figure 3).
Nowadays, although being an extremely promising
research field, H2S cannot be considered among the drugs
possibly available in the very next future.
5. Conclusions
Nowadays, reduced bone quality and an increased fracture
risk should be considered among the possible complications
of T2DM. In T2DM individuals, the risk of fractures is
increased for a given BMD and bone turnover markers are
relatively low in these patients. These features explain the dif-
ficulty in identifying patients at high fracture risk, since phy-
sicians could not rely on the BMD measurement and/or on
bone turnover assessment.
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Figure 3: Cortisol milieu and bone fragility in type 2 diabetes mellitus (T2DM). In T2DM patients, an increased (even though still
within the normal range) cortisol secretion is present, particularly in those affected with the diabetic complications, which in turn is
hypothesized to be a trigger for the increased cortisol secretion itself. The sensitizing variants of the glucocorticoid receptor (GR) may
increase the negative effect of cortisol on both T2DM control and bone metabolism, contributing to the shift in the balance between
osteoblastogenesis and adipogenesis of mesenchymal stem cells in bone. The degree of the interconversion of cortisone in cortisol, due to
the activity of the 11βhydroxysteroidodehydrogenase type 1 (11HSD1), may influence bone metabolism in T2DM. Indeed, in humans, the
selective inhibition of 11HSD1, which has been even suggested as potential treatment for T2DM, has been also demonstrated to improve
diabesity and osteoblast differentiation in a mouse model. Finally, in T2DM, a vicious circle could be hypothesized between the increased
cortisol secretion, peripheral activation, and sensitivity (i.e., “cortisol milieu”) and bone and glycometabolic control. Indeed, the low bone
turnover induced by this activated cortisol milieu could contribute in reducing the undercarboxylated osteocalcin levels, which decrease
and, in turn, may worsen the glycometabolic control, therefore perpetuating the mechanisms leading to reduced bone turnover. The final
effects of these alterations of the cortisol milieu in T2DM may be on one side of the reduction of bone quality, since the low bone
turnover reduces the possibility of the microcrack repairing, and, on the other side, the worsening of the T2DM complications that
ultimately could lead to an increased risk of falls. The reduction of bone quality together with the increased risk of falls is among the most
important factors associated with bone fragility in T2DM.
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Notwithstanding the current limitations, the increasing
knowledge regarding the pathophysiology of the T2DM-
related bone damage gives us some information regarding
which T2DM individual may be at higher risk for bone fragil-
ity. Indeed, T2DM patients with longer (≥10 years) disease
duration, insulin use, poor glycometabolic control, and dia-
betic complications are predisposed to fracture and, in these
subjects, beside the BMD determination, looking for verte-
bral morphometric fracture is advisable. Therefore, in the
authors’ opinion, a spinal and femur BMD determination
by DXA spinal and femur BMD evaluation should be done
in T2DM patients in the presence of clinical fragility fractures
and/or a morphometric vertebral fracture and/or with a long
T2DM duration (i.e., >10 years) and/or insulin use and/or
T2DM-related chronic complication(s).
In the future, evaluating the ROS and AGE levels and the
degree of cortisol secretion, peripheral activation, and sensi-
tivity could increase our ability in predicting the fracture risk
in the single T2D patient. In addition, a better understanding
of the mechanisms leading to bone fragility in T2DM, such as
the bone marrow fat, adipokine production, and cortisol
milieu could consent to both the development of drugs able
to reduce the fracture risk in T2DM and individuate those
antidiabetic drugs more prone to damage the skeletal tissue.
In this regard, the clinical similarities between bone damage
in glucocorticoid-induced osteoporosis and T2D-related
bone involvement seem to find some biological confirmation.
Indeed, very recent data show that in rats, dexamethasone
decreases serum H2S and two key H2S-generating enzymes
in the bone marrow and the H2S treatment significantly
relieved the inhibitory effect of dexamethasone on bone for-
mation [162]. Therefore, it is possible to hypothesize that
the reduced H2S levels in T2DM may depend on the
increased cortisol levels at least in some diabetic patients.
In general, it is conceivable that the mechanisms underly-
ing bone fragility are different among patients with T2DM.
Therefore, the identification of the main cause of bone fragil-
ity in the single patient may consent to personalize the diag-
nostic approach and treatment of choice in T2DM patients at
risk for fracture.
Conflicts of Interest
The authors declare that they have no competing interests.
Authors’ Contributions
All authors contributed equally to the literature review and
drafting of the manuscript. All authors approved the last ver-
sion of the manuscript.
Acknowledgments
This work has been partially supported by the following
grants to Iacopo Chiodini: Istituto Auxologico Italiano
(Grant PRECOR Study 2019_01_29_06) and Ministry of
Health RF-2016-02362238.
References
[1] R. J. Valderrábano and M. I. Linares, “Diabetes mellitus and
bone health: epidemiology, etiology and implications for frac-
ture risk stratification,” Clinical Diabetes and Endocrinology,
vol. 4, no. 1, 2018.
[2] N. Napoli, M. Chandran, D. D. Pierroz, B. Abrahamsen,
A. V. Schwartz, and S. L. Ferrari, “Mechanisms of diabetes
mellitus-induced bone fragilityMechanisms of diabetes
mellitus-induced bone fragility,” Nature Reviews. Endocri-
nology, vol. 13, no. 4, pp. 208–219, 2017.
[3] P. Vestergaard, “Discrepancies in bone mineral density and
fracture risk in patients with type 1 and type 2 diabetes—a
meta-analysis,” Osteoporosis International, vol. 18, no. 4,
pp. 427–444, 2007.
[4] M. Janghorbani, R. M. van Dam, W. C. Willett, and F. B. Hu,
“Systematic review of type 1 and type 2 diabetes mellitus and
risk of fracture,” American Journal of Epidemiology, vol. 166,
no. 5, pp. 495–505, 2007.
[5] Y. Fan, F. Wei, Y. Lang, and Y. Liu, “Diabetes mellitus and
risk of hip fractures: a meta-analysis,” Osteoporosis Interna-
tional, vol. 27, no. 1, pp. 219–228, 2016.
[6] M. Yamamoto, T. Yamaguchi, M. Yamauchi, H. Kaji, and
T. Sugimoto, “Diabetic patients have an increased risk of ver-
tebral fractures independent of BMD or diabetic complica-
tions,” Journal of Bone and Mineral Research, vol. 24, no. 4,
pp. 702–709, 2009.
[7] J. Wang, W. You, Z. Jing, R. Wang, Z. Fu, and Y. Wang,
“Increased risk of vertebral fracture in patients with diabetes:
a meta-analysis of cohort studies,” International Orthopae-
dics, vol. 40, no. 6, pp. 1299–1307, 2016.
[8] V. V. Zhukouskaya, C. Eller-Vainicher, A. Gaudio et al., “In
postmenopausal female subjects with type 2 diabetes mellitus,
vertebral fractures are independently associated with cortisol
secretion and sensitivity,” The Journal of Clinical Endocrinol-
ogy & Metabolism, vol. 100, no. 4, pp. 1417–1425, 2015.
[9] L. M. Giangregorio, W. D. Leslie, L. M. Lix et al., “FRAX
underestimates fracture risk in patients with diabetes,” Jour-
nal of Bone and Mineral Research, vol. 27, no. 2, pp. 301–
308, 2012.
[10] V. Carnevale, S. Morano, A. Fontana et al., “Assessment of
fracture risk by the FRAX algorithm in men and women with
and without type 2 diabetes mellitus: a cross-sectional study,”
Diabetes/Metabolism Research and Reviews, vol. 30, no. 4,
pp. 313–322, 2014.
[11] M. Saito and K. Marumo, “Collagen cross-links as a determi-
nant of bone quality: a possible explanation for bone fragility
in aging, osteoporosis, and diabetes mellitus,” Osteoporosis
International, vol. 21, no. 2, pp. 195–214, 2010.
[12] J. Bełtowski, G. Wójcicka, and A. Jamroz-Wiśniewska,
“Hydrogen sulfide in the regulation of insulin secretion and
insulin sensitivity: Implications for the pathogenesis and
treatment of diabetes mellitus,” Biochemical Pharmacology,
vol. 149, pp. 60–76, 2018, Epub 2018 Jan 4.
[13] I. Chiodini, G. Adda, A. Scillitani et al., “Cortisol secretion in
patients with type 2 diabetes: relationship with chronic com-
plications,” Diabetes Care, vol. 30, no. 1, pp. 83–88, 2006.
[14] C. Eller-Vainicher, A. Scillitani, and I. Chiodini, “Is the
hypothalamic-pituitary-adrenal axis disrupted in type 2
diabetes mellitus and is this relevant for bone health?,”
Endocrine, vol. 58, no. 1, pp. 201-202, 2017.
13Journal of Diabetes Research
[15] C. Eller-Vainicher, A. Falchetti, L. Gennari et al., “DIAGNO-
SIS OF ENDOCRINE DISEASE: Evaluation of bone fragility
in endocrine disorders,” European Journal of Endocrinology,
vol. 180, no. 6, pp. R213–R232, 2019.
[16] D. Merlotti, L. Gennari, F. Dotta, D. Lauro, and R. Nuti,
“Mechanisms of impaired bone strength in type 1 and 2 dia-
betes,” Nutrition, Metabolism, and Cardiovascular Diseases,
vol. 20, no. 9, pp. 683–690, 2010.
[17] A. V. Schwartz, E. Vittinghoff, D. C. Bauer et al., “Association
of BMD and FRAX score with risk of fracture in older adults
with type 2 diabetes,” JAMA, vol. 305, no. 21, pp. 2184–2192,
2011.
[18] C. Poiana and C. Capatina, “Fracture risk assessment in
patients with diabetes mellitus,” Journal of Clinical Densitom-
etry, vol. 20, no. 3, pp. 432–443, 2017.
[19] N. Jiang and W. Xia, “Assessment of bone quality in patients
with diabetes mellitus,” Osteoporosis International, vol. 29,
no. 8, pp. 1721–1736, 2018.
[20] W. D. Leslie, B. Aubry-Rozier, O. Lamy, D. Hans, and for the
Manitoba Bone Density Program, “TBS (trabecular bone
score) and diabetes-related fracture risk,” Journal of Clinical
Endocrinology and Metabolism, vol. 98, no. 2, pp. 602–609,
2013.
[21] V. V. Zhukouskaya, C. Ellen-Vainicher, A. Gaudio et al.,
“The utility of lumbar spine trabecular bone score and
femoral neck bone mineral density for identifying asymp-
tomatic vertebral fractures in well-compensated type 2 dia-
betic patients,” Osteoporosis International, vol. 27, no. 1,
pp. 49–56, 2016.
[22] S. Loubonnick, “HSA: beyond BMD with DXA,” Bone,
vol. 41, no. 1, pp. S9–S12, 2007.
[23] T. Yamaguchi, M. Yamamoto, I. Kanazawa et al., “Quantita-
tive ultrasound and vertebral fractures in patients with type 2
diabetes,” Journal of Bone and Mineral Metabolism, vol. 29,
no. 5, pp. 626–632, 2011.
[24] F. Conti, S. Balducci, L. Pugliese et al., “Correlates of calcaneal
quantitative ultrasound parameters in patients with diabetes:
the study on the assessment of determinants of muscle and
bone strength abnormalities in diabetes,” Journal of Diabetes
Research, vol. 2017, 12 pages, 2017.
[25] J. M. Patsch, A. J. Burghardt, S. P. Yap et al., “Increased cor-
tical porosity in type 2 diabetic postmenopausal women with
fragility fractures,” Journal of Bone and Mineral Research,
vol. 28, no. 2, pp. 313–324, 2013.
[26] E. W. Yu, M. S. Putman, N. Derrico, G. Abrishamanian-
Garcia, J. S. Finkelstein, and M. L. Bouxsein, “Defects in cor-
tical microarchitecture among African-American women
with type 2 diabetes,” Osteoporosis International, vol. 26,
no. 2, pp. 673–679, 2015.
[27] M. Osima, R. Kral, T. T. Borgen et al., “Women with type 2
diabetes mellitus have lower cortical porosity of the proximal
femoral shaft using low-resolution CT than nondiabetic
women, and increasing glucose is associated with reduced
cortical porosity,” Bone, vol. 97, pp. 252–260, 2017.
[28] E. J. Samelson, S. Demissie, L. A. Cupples et al., “Diabetes and
deficits in cortical bone density microarchitecture, and bone
size: Framingham HR-pQCT study,” Journal of Bone and
Mineral Research, vol. 33, no. 1, pp. 54–62, 2018.
[29] J. Paccou, K. A. Ward, K. A. Jameson, E. M. Dennison,
C. Cooper, and M. H. Edwards, “Bone microarchitecture in
men and women with diabetes: the importance of cortical
porosity,” Calcified Tissue International, vol. 98, no. 5,
pp. 465–473, 2016.
[30] M. E. D. Leite, “Histomorphometric analysis of the bone tis-
sue in patients with non-insulin-dependent diabetes,” Revista
do Hospital das Clinicas, vol. 51, no. 1, p. 7, 1996.
[31] J. S. Manavalan, S. Cremers, D. W. Dempster et al., “Circulat-
ing osteogenic precursor cells in type 2 diabetes mellitus,” The
Journal of Clinical Endocrinology and Metabolism, vol. 97,
no. 9, pp. 3240–3250, 2012.
[32] L. A. G. Armas, M. P. Akhter, A. Drincic, and R. R. Recker,
“Trabecular bone histomorphometry in humans with type 1
diabetes mellitus,” Bone, vol. 50, no. 1, pp. 91–96, 2012.
[33] D. Farlay, L. A. G. Armas, E. Gineyts, M. P. Akhter, R. R.
Recker, and G. Boivin, “Nonenzymatic glycation and degree
of mineralization are higher in bone from fractured patients
with type 1 diabetes mellitus,” Journal of Bone and Mineral
Research, vol. 31, no. 1, pp. 190–195, 2016.
[34] M. Yamamoto, T. Yamaguchi, M. Yamauchi, S. Yano, and
T. Sugimoto, “Serum pentosidine levels are positively associ-
ated with the presence of vertebral fractures in postmeno-
pausal women with type 2 diabetes,” The Journal of Clinical
Endocrinology and Metabolism, vol. 93, no. 3, pp. 1013–
1019, 2008.
[35] A. V. Schwartz, P. Garnero, T. A. Hillier et al., “Pentosidine
and increased fracture risk in older adults with type 2 diabe-
tes,” The Journal of Clinical Endocrinology and Metabolism,
vol. 94, no. 7, pp. 2380–2386, 2009.
[36] S. Adami, “Bone health in diabetes: considerations for clinical
management,” Current Medical Research and Opinion,
vol. 25, no. 5, pp. 1057–1072, 2009.
[37] J. Starup-Linde, S. A. Eriksen, S. Lykkeboe, A. Handberg,
and P. Vestergaard, “Biochemical markers of bone turn-
over in diabetes patients — a meta-analysis, and a method-
ological study on the effects of glucose on bone markers,”
Osteoporosis International, vol. 25, no. 6, pp. 1697–1708,
2014.
[38] A. Díaz-López, M. Bulló, M. Juanola-Falgarona et al.,
“Reduced serum concentrations of carboxylated and under-
carboxylated osteocalcin are associated with risk of develop-
ing type 2 diabetes mellitus in a high cardiovascular risk
population: a nested case-control study,” The Journal of Clin-
ical Endocrinology and Metabolism, vol. 98, no. 11, pp. 4524–
4531, 2013.
[39] A. Shu, M. T. Yin, E. Stein et al., “Bone structure and turnover
in type 2 diabetes mellitus,” Osteoporosis International,
vol. 23, no. 2, pp. 635–641, 2012.
[40] M. Yamamoto, T. Yamaguchi, K. Nawata, M. Yamauchi, and
T. Sugimoto, “Decreased PTH levels accompanied by low
bone formation are associated with vertebral fractures in
postmenopausal women with type 2 diabetes,” The Journal
of Clinical Endocrinology and Metabolism, vol. 97, no. 4,
pp. 1277–1284, 2012.
[41] D. M. S. L. Cutrim, F. A. Pereira, F. J. A. . Paula, and M. C.
Foss, “Lack of relationship between glycemic control and
bone mineral density in type 2 diabetes mellitus,” Brazilian
Journal of Medical and Biological Research, vol. 40, no. 2,
pp. 221–227, 2007.
[42] N. C. Thalassinos, P. Hadjiyanni, M. Tzanela, C. Alevizaki,
and D. Philokiprou, “Calcium metabolism in diabetes melli-
tus: effect of improved blood glucose control,” Diabetic Med-
icine, vol. 10, no. 4, pp. 341–344, 1993.
14 Journal of Diabetes Research
[43] R. Q. Ivers, R. G. Cumming, P. Mitchell, A. J. Peduto, and
Blue Mountains Eye Study, “Diabetes and risk of fracture:
The Blue Mountains eye study,” Diabetes Care, vol. 24,
no. 7, pp. 1198–1203, 2001.
[44] M. Janghorbani, D. Feskanich, W. C. Willett, and F. Hu,
“Prospective study of diabetes and risk of hip fracture: the
Nurses’ Health Study,” Diabetes Care, vol. 29, no. 7,
pp. 1573–1578, 2006.
[45] W. D. Leslie, L. M. Lix, H. J. Prior, S. Derksen, C. Metge, and
J. O'Neil, “Biphasic fracture risk in diabetes: a population-
based study,” Bone, vol. 40, no. 6, pp. 1595–1601, 2007.
[46] L. J. Melton III, C. L. Leibson, S. J. Achenbach, T. M.
Therneau, and S. Khosla, “Fracture risk in type 2 diabetes:
update of a population-based study,” Journal of Bone and
Mineral Research, vol. 23, no. 8, pp. 1334–1342, 2008.
[47] A. D. Dede, S. Tournis, I. Dontas, and G. Trovas, “Type 2 dia-
betes mellitus and fracture risk,” Metabolism, vol. 63, no. 12,
pp. 1480–1490, 2014.
[48] A. J. Burghardt, A. S. Issever, A. V. Schwartz et al., “High-res-
olution peripheral quantitative computed tomographic imag-
ing of cortical and trabecular bone microarchitecture in
patients with type 2 diabetes mellitus,” The Journal of Clinical
Endocrinology and Metabolism, vol. 95, no. 11, pp. 5045–
5055, 2010.
[49] L. Oei, M. C. Zillikens, A. Dehghan et al., “High bone mineral
density and fracture risk in type 2 diabetes as skeletal compli-
cations of inadequate glucose control: the Rotterdam study,”
Diabetes Care, vol. 36, no. 6, pp. 1619–1628, 2013.
[50] A. V. Schwartz, K. L. Margolis, D. E. Sellmeyer et al., “Inten-
sive glycemic control is not associated with fractures or falls
in the ACCORD randomized trial,” Diabetes Care, vol. 35,
no. 7, pp. 1525–1531, 2012.
[51] P. Vestergaard, L. Rejnmark, and L. Mosekilde, “Diabetes and
its complications and their relationship with risk of fractures
in type 1 and 2 diabetes,” Calcified Tissue International,
vol. 84, no. 1, pp. 45–55, 2009.
[52] J. H. Kim, M. H. Jung, J. M. Lee, H. S. Son, B. Y. Cha, and S. A.
Chang, “Diabetic peripheral neuropathy is highly associated
with nontraumatic fractures in Korean patients with type 2
diabetes mellitus,” Clinical Endocrinology, vol. 77, no. 1,
pp. 51–55, 2012.
[53] E. S. Strotmeyer, J. A. Cauley, A. V. Schwartz et al., “Nontrau-
matic fracture risk with diabetes mellitus and impaired fast-
ing glucose in older white and black adults: the health,
aging, and body composition study,” Archives of Internal
Medicine, vol. 165, no. 14, pp. 1612–1617, 2005.
[54] A. V. Schwartz, T. A. Hillier, D. E. Sellmeyer et al., “Older
women with diabetes have a higher risk of falls: a prospective
study,” Diabetes Care, vol. 25, no. 10, pp. 1749–1754, 2002.
[55] E. W. Gregg, G. L. Beckles, D. F. Williamson et al., “Diabetes
and physical disability among older U.S. adults,” Diabetes
Care, vol. 23, no. 9, pp. 1272–1277, 2000.
[56] A. Malmivaara, M. Heliövaara, P. Knekt, A. Reunanen,
and A. Aromaa, “Risk factors for injurious falls leading
to hospitalization or death in a cohort of 19,500 adults,”
American Journal of Epidemiology, vol. 138, no. 6, pp. 384–
394, 1993.
[57] C. Sarodnik, S. P. G. Bours, N. C. Schaper, J. P. van den Bergh,
and T. A. C. M. van Geel, “The risks of sarcopenia, falls and
fractures in patients with type 2 diabetes mellitus,”Maturitas,
vol. 109, pp. 70–77, 2018.
[58] S. W. Park, B. H. Goodpaster, E. S. Strotmeyer et al.,
“Accelerated loss of skeletal muscle strength in older adults
with type 2 diabetes: the health, aging, and body composi-
tion study,” Diabetes Care, vol. 30, no. 6, pp. 1507–1512,
2007.
[59] T. N. Kim, M. S. Park, S. J. Yang et al., “Prevalence and deter-
minant factors of sarcopenia in patients with type 2 diabetes:
the Korean Sarcopenic Obesity Study (KSOS),” Diabetes
Care, vol. 33, no. 7, pp. 1497–1499, 2010.
[60] G. Orlando, S. Balducci, I. Bazzucchi, G. Pugliese, and
M. Sacchetti, “Neuromuscular dysfunction in type 2 diabetes:
underlying mechanisms and effect of resistance training,”
Diabetes/Metabolism Research and Reviews, vol. 32, no. 1,
pp. 40–50, 2016.
[61] S. E. Inzucchi, R. M. Bergenstal, J. B. Buse et al., “Manage-
ment of hyperglycemia in type 2 diabetes, 2015: a patient-
centered approach: update to a position statement of the
American Diabetes Association and the European Associa-
tion for the Study of Diabetes,” Diabetes Care, vol. 38, no. 1,
pp. 140–149, 2014.
[62] D. Kirpichnikov, S. I. McFarlane, and J. R. Sowers, “Metfor-
min: an update,” Annals of Internal Medicine, vol. 137,
no. 1, pp. 25–33, 2002.
[63] A. Palermo, L. D’Onofrio, R. Eastell, A. V. Schwartz,
P. Pozzilli, and N. Napoli, “Oral anti-diabetic drugs and frac-
ture risk, cut to the bone: safe or dangerous? A narrative
review,” Osteoporosis International, vol. 26, no. 8, pp. 2073–
2089, 2015.
[64] N. Napoli, E. S. Strotmeyer, K. E. Ensrud et al., “Fracture risk
in diabetic elderly men: the MrOS study,” Diabetologia,
vol. 57, no. 10, pp. 2057–2065, 2014.
[65] P. Vestergaard, L. Rejnmark, and L. Mosekilde, “Relative
fracture risk in patients with diabetes mellitus, and the impact
of insulin and oral antidiabetic medication on relative frac-
ture risk,” Diabetologia, vol. 48, no. 7, pp. 1292–1299, 2005.
[66] H. M. Colhoun, S. J. Livingstone, H. C. Looker et al., “Hospi-
talised hip fracture risk with rosiglitazone and pioglitazone
use compared with other glucose-lowering drugs,” Diabetolo-
gia, vol. 55, no. 11, pp. 2929–2937, 2012.
[67] S. S. Johnston, C. Conner, M. Aagren, K. Ruiz, and
J. Bouchard, “Association between hypoglycaemic events
and fall-related fractures in Medicare-covered patients with
type 2 diabetes,” Diabetes, Obesity & Metabolism, vol. 14,
no. 7, pp. 634–643, 2012.
[68] I. J. Douglas, S. J. Evans, S. Pocock, and L. Smeeth, “The risk
of fractures associated with thiazolidinediones: a self-
controlled case-series study,” PLoS Medicine, vol. 6, no. 9,
article e1000154, 2009.
[69] I. Kanazawa, T. Yamaguchi, M. Yamamoto, and T. Sugimoto,
“Relationship between treatments with insulin and oral
hypoglycemic agents versus the presence of vertebral frac-
tures in type 2 diabetes mellitus,” Journal of Bone and Min-
eral Metabolism, vol. 28, no. 5, pp. 554–560, 2010.
[70] A. V. Schwartz and D. E. Sellmeyer, “Thiazolidinedione ther-
apy gets complicated: is bone loss the price of improved insu-
lin resistance?,” Diabetes Care, vol. 30, no. 6, pp. 1670-1671,
2007.
[71] O. P. Lazarenko, S. O. Rzonca, W. R. Hogue, F. L. Swain, L. J.
Suva, and B. Lecka-Czernik, “Rosiglitazone induces decreases
in bone mass and strength that are reminiscent of aged bone,”
Endocrinology, vol. 148, no. 6, pp. 2669–2680, 2007.
15Journal of Diabetes Research
[72] K. R. Shockley, O. P. Lazarenko, P. J. Czernik, C. J. Rosen,
G. A. Churchill, and B. Lecka-Czernik, “PPARγ2 nuclear
receptor controls multiple regulatory pathways of osteoblast
differentiation frommarrowmesenchymal stem cells,” Journal
of Cellular Biochemistry, vol. 106, no. 2, pp. 232–246, 2009.
[73] S. E. Kahn, B. Zinman, J. M. Lachin et al., “Rosiglitazone-
associated fractures in type 2 diabetes: an Analysis from A
Diabetes Outcome Progression Trial (ADOPT),” Diabetes
Care, vol. 31, no. 5, pp. 845–851, 2008.
[74] C. R. Dormuth, G. Carney, B. Carleton, K. Bassett, and J. M.
Wright, “Thiazolidinediones and fractures in men and
women,” Archives of Internal Medicine, vol. 169, no. 15,
pp. 1395–1402, 2009.
[75] Z. N. Zhu, Y. F. Jiang, and T. Ding, “Risk of fracture with thia-
zolidinediones: an updated meta-analysis of randomized
clinical trials,” Bone, vol. 68, pp. 115–123, 2014.
[76] H. H. Chen, M. H. Horng, S. Y. Yeh et al., “Glycemic control
with thiazolidinedione is associated with fracture of T2DM
patients,” PLoS One, vol. 10, no. 8, article e0135530, 2015.
[77] E. O. Billington, A. Grey, and M. J. Bolland, “The effect of
thiazolidinediones on bone mineral density and bone turn-
over: systematic review and meta-analysis,” Diabetologia,
vol. 58, no. 10, pp. 2238–2246, 2015.
[78] F. K. Knop, T. Vilsbøll, P. V. Højberg et al., “Reduced incretin
effect in type 2 diabetes: cause or consequence of the diabetic
state?,” Diabetes, vol. 56, no. 8, pp. 1951–1959, 2007.
[79] D. J. Drucker and M. A. Nauck, “The incretin system:
glucagon-like peptide-1 receptor agonists and dipeptidyl
peptidase-4 inhibitors in type 2 diabetes,” Lancet, vol. 368,
no. 9548, pp. 1696–1705, 2006.
[80] E. L. Pacheco-Pantoja, L. R. Ranganath, J. A. Gallagher, P. J.
M. Wilson, and W. D. Fraser, “Receptors and effects of gut
hormones in three osteoblastic cell lines,” BMC Physiology,
vol. 11, no. 1, p. 12, 2011.
[81] B. Nuche-Berenguer, S. Portal-Núñez, P. Moreno et al.,
“Presence of a functional receptor for GLP 1 in osteoblastic
cells, independent of the cAMP-linked GLP 1 receptor,” Jour-
nal of Cellular Physiology, vol. 225, no. 2, pp. 585–592, 2010.
[82] C. Sanz, P. Vázquez, C. Blázquez, P. A. Barrio, M. D. M. Alva-
rez, and E. Blázquez, “Signaling and biological effects of
glucagon-like peptide 1 on the differentiation of mesenchy-
mal stem cells from human bone marrow,” American Journal
of Physiology. Endocrinology and Metabolism, vol. 298, no. 3,
pp. E634–E643, 2010.
[83] J. Y. Kim, S. K. Lee, K. J. Jo et al., “Exendin-4 increases bone
mineral density in type 2 diabetic OLETF rats potentially
through the down-regulation of SOST/sclerostin in osteo-
cytes,” Life Sciences, vol. 92, no. 10, pp. 533–540, 2013.
[84] X. Ma, J. Meng, M. Jia et al., “Exendin-4, a glucagon-like
peptide-1 receptor agonist, prevents osteopenia by promot-
ing bone formation and suppressing bone resorption in aged
ovariectomized rats,” Journal of Bone and Mineral Research,
vol. 28, no. 7, pp. 1641–1652, 2013.
[85] B. Su, H. Sheng, M. Zhang et al., “Risk of bone fractures asso-
ciated with glucagon-like peptide-1 receptor agonists' treat-
ment: a meta-analysis of randomized controlled trials,”
Endocrine, vol. 48, no. 1, pp. 107–115, 2015.
[86] G. Mabilleau, A. Mieczkowska, and D. Chappard, “Use of
glucagon-like peptide-1 receptor agonists and bone fractures:
a meta-analysis of randomized clinical trials,” Journal of Dia-
betes, vol. 6, no. 3, pp. 260–266, 2014.
[87] M. P. Gilbert, M. Marre, J. J. Holst et al., “Comparison of the
LONG-TERM effects of liraglutide and GLIMEPIRIDE
monotherapy on bone mineral density in patients with type
2 diabetes,” Endocrine Practice, vol. 22, no. 4, pp. 406–411,
2016.
[88] M. Monami, B. Cresci, A. Colombini et al., “Bone fractures
and hypoglycemic treatment in type 2 diabetic patients: a
case-control study,” Diabetes Care, vol. 31, no. 2, pp. 199–
203, 2008.
[89] S. Dombrowski, K. Kostev, and L. Jacob, “Use of dipeptidyl
peptidase-4 inhibitors and risk of bone fracture in patients
with type 2 diabetes in Germany—a retrospective analysis
of real-world data,” Osteoporosis International, vol. 28,
no. 8, pp. 2421–2428, 2017.
[90] J. Mamza, C. Marlin, C. Wang, K. Chokkalingam, and I. Idris,
“DPP-4 inhibitor therapy and bone fractures in people with
Type 2 diabetes – A systematic review and meta-analysis,”
Diabetes Research and Clinical Practice, vol. 116, pp. 288–
298, 2016.
[91] A. Ptaszynska, K. M. Johnsson, S. J. Parikh, T.W. A. de Bruin,
A. M. Apanovitch, and J. F. List, “Safety profile of dapagliflo-
zin for type 2 diabetes: pooled analysis of clinical studies for
overall safety and rare events,” Drug Safety, vol. 37, no. 10,
pp. 815–829, 2014.
[92] D. Ruanpeng, P. Ungprasert, J. Sangtian, and
T. Harindhanavudhi, “Sodium-glucose cotransporter 2
(SGLT2) inhibitors and fracture risk in patients with type 2
diabetes mellitus: a meta-analysis,” Diabetes/Metabolism
Research and Reviews, vol. 33, no. 6, 2017.
[93] H. L. Tang, D. D. Li, J. J. Zhang et al., “Lack of evidence for a
harmful effect of sodium-glucose cotransporter 2 (SGLT2)
inhibitors on fracture risk among type 2 diabetes patients: a
network and cumulative meta-analysis of randomized con-
trolled trials,” Diabetes, Obesity & Metabolism, vol. 18,
no. 12, pp. 1199–1206, 2016.
[94] S. I. Taylor, J. E. Blau, and K. I. Rother, “Possible adverse
effects of SGLT2 inhibitors on bone,” The lancet Diabetes &
endocrinology, vol. 3, no. 1, pp. 8–10, 2015.
[95] D. E. Kohan, P. Fioretto, W. Tang, and J. F. List, “Long-term
study of patients with type 2 diabetes and moderate renal
impairment shows that dapagliflozin reduces weight and
blood pressure but does not improve glycemic control,” Kid-
ney International, vol. 85, no. 4, pp. 962–971, 2014.
[96] N. B. Watts, J. P. Bilezikian, K. Usiskin et al., “Effects of cana-
gliflozin on fracture risk in patients with type 2 diabetes mel-
litus,” The Journal of Clinical Endocrinology and Metabolism,
vol. 101, no. 1, pp. 157–166, 2016.
[97] C. Conte, S. Epstein, and N. Napoli, “Insulin resistance and
bone: a biological partnership,” Acta Diabetologica, vol. 55,
no. 4, pp. 305–314, 2018.
[98] T. Akune, N. Ogata, K. Hoshi et al., “Insulin receptor
substrate-2 maintains predominance of anabolic function
over catabolic function of osteoblasts,” The Journal of Cell
Biology, vol. 159, no. 1, pp. 147–156, 2002.
[99] J. Cornish, K. E. Callon, and I. R. Reid, “Insulin increases his-
tomorphometric indices of bone formation in vivo,” Calcified
Tissue International, vol. 59, no. 6, pp. 492–495, 1996.
[100] T. B. Stage, M. M. H. Christensen, N. R. Jørgensen et al.,
“Effects of metformin, rosiglitazone and insulin on bone
metabolism in patients with type 2 diabetes,” Bone, vol. 112,
pp. 35–41, 2018.
16 Journal of Diabetes Research
[101] A. V. Schwartz, D. E. Sellmeyer, K. E. Ensrud et al., “Older
women with diabetes have an increased risk of fracture: A
prospective study,” The Journal of Clinical Endocrinology
and Metabolism, vol. 86, no. 1, pp. 32–38, 2001.
[102] E. Losada, B. Soldevila, M. S. Ali et al., “Real-world antidia-
betic drug use and fracture risk in 12,277 patients with type
2 diabetes mellitus: a nested case-control study,” Osteoporosis
International, vol. 29, no. 9, pp. 2079–2086, 2018.
[103] S. Pscherer, K. Kostev, F. W. Dippel, and W. Rathmann,
“Fracture risk in patients with type 2 diabetes under different
antidiabetic treatment regimens: a retrospective database
analysis in primary care,” Diabetes Metab Syndr Obes,
vol. 9, pp. 17–23, 2016.
[104] T. E. Rinker, T. M. Hammoudi, M. L. Kemp, H. Lu, and J. S.
Temenoff, “Interactions between mesenchymal stem cells,
adipocytes, and osteoblasts in a 3D tri-culture model of
hyperglycemic conditions in the bone marrowmicroenviron-
ment,” Integr Biol (Camb), vol. 6, no. 3, pp. 324–337, 2014.
[105] Y.-F. Zhao, D.-L. Zeng, L.-G. Xia et al., “Osteogenic potential
of bone marrow stromal cells derived from streptozotocin
induced diabetic rats,” International Journal of Molecular
Medicine, vol. 31, no. 3, pp. 614–620, 2013.
[106] A. Wang, R. J. Midura, A. Vasanji, A. J. Wang, and V. C.
Hascall, “Hyperglycemia diverts dividing osteoblastic precur-
sor cells to an adipogenic pathway and induces synthesis of a
hyaluronan matrix that is adhesive for monocytes,” The Jour-
nal of Biological Chemistry, vol. 289, no. 16, pp. 11410–
11420, 2014.
[107] A. García-Hernández, H. Arzate, I. Gil-Chavarría, R. Rojo,
and L. Moreno-Fierros, “High glucose concentrations alter
the biomineralization process in human osteoblastic cells,”
Bone, vol. 50, no. 1, pp. 276–288, 2012.
[108] S. Ehnert, T. Freude, C. Ihle et al., “Factors circulating in the
blood of type 2 diabetes mellitus patients affect osteoblast
maturation – Description of a novel in vitro model,” Experi-
mental Cell Research, vol. 332, no. 2, pp. 247–258, 2015.
[109] M. Hie, N. Iitsuka, T. Otsuka, and I. Tsukamoto, “Insulin-
dependent diabetes mellitus decreases osteoblastogenesis
associated with the inhibition of Wnt signaling through
increased expression of Sost and Dkk1 and inhibition of
Akt activation,” International Journal of Molecular Medicine,
vol. 28, pp. 455–462, 2011.
[110] C. Fu, X. Zhang, F. Ye, and J. Yang, “High insulin levels in
KK-ay diabetic mice cause increased cortical bone mass and
impaired trabecular micro-structure,” International Journal
of Molecular Sciences, vol. 16, no. 12, pp. 8213–8226, 2015.
[111] M. Hie, M. Shimono, K. Fujii, and I. Tsukamoto, “Increased
cathepsin K and tartrate-resistant acid phosphatase expres-
sion in bone of streptozotocin-induced diabetic rats,” Bone,
vol. 41, no. 6, pp. 1045–1050, 2007.
[112] H. Fujii, Y. Hamada, and M. Fukagawa, “Bone formation in
spontaneously diabetic Torii-newly established model of
non- obese type 2 diabetes rats,” Bone, vol. 42, no. 2,
pp. 372–379, 2008.
[113] H. Y. Won, J.-A. Lee, Z. S. Park et al., “Prominent bone loss
mediated by RANKL and IL-17 produced by CD4+ T cells
in TallyHo/JngJ mice,” PLoS One, vol. 6, no. 3, article
e18168, 2011.
[114] T. Neumann, L. C. Hofbauer, M. Rauner et al., “Clinical and
endocrine correlates of circulating sclerostin levels in patients
with type 1 diabetes mellitus,” Clinical Endocrinology, vol. 80,
no. 5, pp. 649–655, 2014.
[115] M. Yamamoto, M. Yamauchi, and T. Sugimoto, “Elevated
sclerostin levels are associated with vertebral fractures in
patients with type 2 diabetes mellitus,” The Journal of Clinical
Endocrinology and Metabolism, vol. 98, no. 10, pp. 4030–
4037, 2013.
[116] M. A. Piccinin and Z. A. Khan, “Pathophysiological role of
enhanced bone marrow adipogenesis in diabetic complica-
tions,” Adipocytes, vol. 3, no. 4, pp. 263–272, 2014.
[117] A. Palermo, L. D’Onofrio, R. Buzzetti, S. Manfrini, and
N. Napoli, “Pathophysiology of Bone Fragility in Patients
with Diabetes,” Calcified Tissue International, vol. 100,
no. 2, pp. 122–132, 2017, Epub 2017 Feb 8.
[118] G. E. Hein, “Glycation endproducts in osteoporosis — is
there a pathophysiologic importance?,” Clinica Chimica Acta,
vol. 371, no. 1-2, pp. 32–36, 2006.
[119] K. Okazaki, T. Yamaguchi, K.-I. Tanaka et al., “Advanced
glycation end products (AGEs), but not high glucose, inhibit
the osteoblastic differentiation of mouse stromal ST2 cells
through the suppression of osterix expression, and inhibit cell
growth and increasing cell apoptosis,” Calcified Tissue Inter-
national, vol. 91, no. 4, pp. 286–296, 2012.
[120] J. H. Kim, Y.-Y. Kim, and S.-J. Kim, “High glucose inhibits
gene expression of tyrosyl-tRNA synthetase in osteoblast
cells,” Methods and Findings in Experimental and Clinical
Pharmacology, vol. 31, no. 10, pp. 639–644, 2009.
[121] S. Ehnert, T. Freude, C. Ihle et al., “Factors circulating in the
blood of type 2 diabetes mellitus patients affect osteoblast
maturation - description of a novel in vitro model,” Experi-
mental Cell Research, vol. 332, no. 2, pp. 247–258, 2015.
[122] T. Kasahara, S. Imai, H. Kojima et al., “Malfunction of bone
marrow-derived osteoclasts and the delay of bone fracture
healing in diabetic mice,” Bone, vol. 47, no. 3, pp. 617–625,
2010.
[123] J. Xu, F. Yue, J. Wang, L. Chen, and W. Qi, “High glucose
inhibits receptor activator of nuclear factor- κB ligand-
induced osteoclast differentiation via downregulation of
v- ATPase V0 subunit d2 and dendritic cell-specific trans-
membrane protein,” Molecular Medicine Reports, vol. 11,
no. 2, pp. 865–870, 2015.
[124] C. Hamann, C. Goettsch, J. Mettelsiefen et al., “Delayed bone
regeneration and low bone mass in a rat model of insulin-
resistant type 2 diabetes mellitus is due to impaired osteoblast
function,” American Journal of Physiology. Endocrinology
and Metabolism, vol. 301, no. 6, pp. E1220–E1228, 2011.
[125] M. Saito and K. Marumo, “Bone quality in diabetes,” Fron-
tiers in Endocrinology, vol. 4, p. 72, 2013.
[126] W. D. Leslie, M. R. Rubin, A. V. Schwartz, and J. A. Kanis,
“Type 2 diabetes and bone,” Journal of Bone and Mineral
Research, vol. 27, no. 11, pp. 2231–2237, 2012.
[127] M. Saito, K. Fujii, Y. Mori, and K. Marumo, “Role of collagen
enzymatic and glycation induced cross-links as a determinant
of bone quality in spontaneously diabetic WBN/Kob rats,”
Osteoporosis International, vol. 17, no. 10, pp. 1514–1523, 2006.
[128] A. D. McCarthy, S. B. Etcheverry, and A. M. Cortizo, “Effect
of advanced glycation endproducts on the secretion of
insulin-like growth factor-I and its binding proteins: role in
osteoblast development,” Acta Diabetologica, vol. 38, no. 3,
pp. 113–122, 2001.
[129] M. Terada, M. Inaba, Y. Yano et al., “Growth-inhibitory effect
of a high glucose concentration on osteoblast-like cells,”
Bone, vol. 22, no. 1, pp. 17–23, 1998.
17Journal of Diabetes Research
[130] I. Kanazawa, T. Yamaguchi, and T. Sugimoto, “Serum
insulin-like growth factor-I is a marker for assessing the
severity of vertebral fractures in postmenopausal women with
type 2 diabetes mellitus,” Osteoporosis International, vol. 22,
no. 4, pp. 1191–1198, 2011.
[131] L. Gilbert, X. He, P. Farmer et al., “Inhibition of osteoblast
differentiation by tumor necrosis factor-α,” Endocrinology,
vol. 141, no. 11, pp. 3956–3964, 2000.
[132] H. Glantschnig, J. E. Fisher, G. Wesolowski, G. A. Rodan, and
A. A. Reszka, “M-CSF, TNF _α_ and RANK ligand promote
osteoclast survival by signaling through mTOR/S6 kinase,”
Cell Death and Differentiation, vol. 10, no. 10, pp. 1165–
1177, 2003.
[133] S. C. Manolagas, “From estrogen-centric to aging and oxida-
tive stress: a revised perspective of the pathogenesis of osteo-
porosis,” Endocrine Reviews, vol. 31, no. 3, pp. 266–300, 2010.
[134] M. Giralt and F. Villarroya, “White, brown, beige/brite: dif-
ferent adipose cells for different functions?,” Endocrinology,
vol. 154, no. 9, pp. 2992–3000, 2013.
[135] S. Rahman, Y. Lu, P. J. Czernik, C. J. Rosen, S. Enerback, and
B. Lecka-Czernik, “Inducible brown adipose tissue, or beige
fat, is anabolic for the skeleton,” Endocrinology, vol. 154,
no. 8, pp. 2687–2701, 2013.
[136] R. Singh, M. Braga, and S. Pervin, “Regulation of brown
adipocyte metabolism by myostatin/follistatin signaling,”
Frontiers in Cell and Development Biology, vol. 2, p. 60, 2014.
[137] C. Weyer, T. Funahashi, S. Tanaka et al., “Hypoadiponectine-
mia in obesity and type 2 diabetes: close association with
insulin resistance and hyperinsulinemia,” The Journal of
Clinical Endocrinology and Metabolism, vol. 86, no. 5,
pp. 1930–1935, 2001.
[138] G. A. Williams, Y. Wang, K. E. Callon et al., “In vitro and
in vivo effects of adiponectin on bone,” Endocrinology,
vol. 150, no. 8, pp. 3603–3610, 2009.
[139] L. Lenchik, T. C. Register, F. C. Hsu et al., “Adiponectin as a
novel determinant of bone mineral density and visceral fat,”
Bone, vol. 33, no. 4, pp. 646–651, 2003.
[140] N. Napoli, C. Pedone, P. Pozzilli, F. Lauretani, L. Ferrucci, and
R. A. Incalzi, “Adiponectin and bone mass density: the
InCHIANTI study,” Bone, vol. 47, no. 6, pp. 1001–1005, 2010.
[141] T. Tamura, M. Yoneda, K. Yamane et al., “Serum leptin and
adiponectin are positively associated with bone mineral den-
sity at the distal radius in patients with type 2 diabetes melli-
tus,” Metabolism, vol. 56, no. 5, pp. 623–628, 2007.
[142] M.W. Hamrick and S. L. Ferrari, “Leptin and the sympathetic
connection of fat to bone,”Osteoporosis International, vol. 19,
no. 7, pp. 905–912, 2008.
[143] M. J. Devlin and C. J. Rosen, “The bone–fat interface: basic
and clinical implications of marrow adiposity,” The Lancet
Diabetes and Endocrinology, vol. 3, no. 2, pp. 141–147, 2015.
[144] M. Ferron and J. Lacombe, “Regulation of energy metabolism
by the skeleton: osteocalcin and beyond,” Archives of Bio-
chemistry and Biophysics, vol. 561, pp. 137–146, 2014.
[145] J. E. Compston, J. Flahive, F. H. Hooven et al., “Obesity,
health-care utilization, and health-related quality of life after
fracture in postmenopausal women: global longitudinal study
of osteoporosis in women (GLOW),” Calcified Tissue Inter-
national, vol. 94, no. 2, pp. 223–231, 2014.
[146] J. S. Walsh and T. Vilaca, “Obesity, Type 2 Diabetes and Bone
in Adults,” Calcified Tissue International, vol. 100, no. 5,
pp. 528–535, 2017.
[147] N. Binkley, D. Krueger, and B. Buehring, “What’s in a name
revisited: should osteoporosis and sarcopenia be considered
components of “dysmobility syndrome?”,” Osteoporosis
International, vol. 24, no. 12, pp. 2955–2959, 2013.
[148] A. C. Looker, “Dysmobility syndrome and mortality risk in
US men and women age 50 years and older,” Osteoporosis
International, vol. 26, no. 1, pp. 93–102, 2015.
[149] K. D. Hill, K. Farrier, M. Russell, and E. Burton, “Dysmobility
syndrome: current perspectives,” Clinical Interventions in
Aging, vol. Volume 12, pp. 145–152, 2017.
[150] L. Manenschijn, E. L. T. van den Akker, S. W. J. Lamberts,
and E. F. C. van Rossum, “Clinical features associated with
glucocorticoid receptor Polymorphisms,” Annals of the New
York Academy of Sciences, vol. 1179, no. 1, pp. 179–198, 2009.
[151] L. Han, B. Wang, R. Wang, S. Gong, G. Chen, and W. Xu,
“The shift in the balance between osteoblastogenesis and adi-
pogenesis of mesenchymal stem cells mediated by glucocorti-
coid receptor,” Stem Cell Research & Therapy, vol. 10, no. 1,
p. 377, 2019.
[152] NBSPJ. Rosenstock, S. Banarer, V. A. Fonseca et al., “The
11- -Hydroxysteroid dehydrogenase type 1 inhibitor
INCB13739 improves hyperglycemia in patients with type 2
diabetes inadequately controlled by metformin monother-
apy,” Diabetes Care, vol. 33, no. 7, pp. 1516–1522, 2010.
[153] J. S. Park, S. J. Bae, S.-W. Choi et al., “A novel 11β-HSD1
inhibitor improves diabesity and osteoblast differentiation,”
Molecular Endocrinology, vol. 52, no. 2, pp. 191–202, 2014.
[154] G. Karsenty and E. N. Olson, “Bone and muscle endocrine
functions: unexpected paradigms of inter-organ communica-
tion,” Cell, vol. 164, no. 6, pp. 1248–1256, 2016.
[155] P. Kamoun, “Endogenous production of hydrogen sulfide in
mammals,” Amino Acids, vol. 26, no. 3, pp. 243–254, 2004.
[156] S. Gheibi, A. P. Samsonov, S. Gheibi, A. B. Vazquez, and
K. Kashfi, “Regulation of carbohydrate metabolism by nitric
oxide and hydrogen sulfide: Implications in diabetes,” Bio-
chemical Pharmacology, p. 113819, 2020.
[157] J. Behera, S. C. Tyagi, and N. Tyagi, “Role of hydrogen sulfide
in the musculoskeletal system,” Bone, vol. 124, pp. 33–39,
2019.
[158] J. Behera, K. E. Kelly, M. J. voor, N. Metreveli, S. C. Tyagi, and
N. Tyagi, “Hydrogen sulfide promotes bone homeostasis by
balancing inflammatory cytokine signaling in CBS-deficient
mice through an epigenetic mechanism,” Scientific Reports,
vol. 8, no. 1, p. 15226, 2018.
[159] Y. Liu, R. Yang, X. Liu et al., “Hydrogen Sulfide Maintains
Mesenchymal Stem Cell Function and Bone Homeostasis
via Regulation of Ca2+ Channel Sulfhydration,” Cell Stem
Cell, vol. 15, no. 1, pp. 66–78, 2014.
[160] F. Grassi, A. M. Tyagi, J. W. Calvert et al., “Hydrogen sulfide
is a novel regulator of bone formation implicated in the bone
loss induced by estrogen deficiency,” Journal of Bone and
Mineral Research, vol. 31, no. 5, pp. 949–963, 2016.
[161] M. S. Bitar, J. Nader, W. al-Ali, A. al Madhoun, H. Arefanian,
and F. al-Mulla, “Hydrogen sulfide donor NaHS improves
metabolism and reduces muscle atrophy in type 2 diabetes:
implication for understanding sarcopenic pathophysiology,”
Oxidative Medicine and Cellular Longevity, vol. 2018, Article
ID 6825452, 17 pages, 2018.
[162] J. Ma, C. Shi, Z. Liu et al., “Hydrogen sulfide is a novel regu-
lator implicated in glucocorticoids-inhibited bone forma-
tion,” Aging, vol. 11, no. 18, pp. 7537–7552, 2019.
18 Journal of Diabetes Research
